Akorn Rifampin Capsules Recalled for Impurity Specification Failure
Akorn is recalling Rifampin Capsules USP 300 mg (30-, 60-, and 100-count bottles) distributed nationwide because finished product exceeds the interim limit for 1-Methyl-4-Nitrosopiperazine impurity. The recall affects approximately 177,439 bottles.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving failed impurity specifications without reported hospitalizations or injuries. Per the rubric, risk-of-harm products where injury has not yet been reported merit a High severity score.
Plain-English summary
Akorn, Inc. is recalling Rifampin Capsules, USP, 300 mg, in 30-count, 60-count, and 100-count bottles, distributed nationwide and in Puerto Rico. Approximately 177,439 bottles are affected.
The finished product in certain lots exceeds the interim limit of 5 ppm for 1-Methyl-4-Nitrosopiperazine (MNP). The impurity specification failure was detected through quality control testing.
Patients with affected batches should consult their healthcare provider or pharmacist. A complete list of affected lot numbers and expiration dates is available from the FDA.
The recalled product
- Product
- Rifampin Capsules, USP, 300 mg, a) 30-count bottle (NDC 61748-018-30), b) 60-count bottle (NDC 61748-018-60), c) 100-count bottle (NDC 61748-018-01), Rx only, Distributed by: Akorn Operating Company, LLC, Gurnee, IL 60031.
- Manufacturer
- Akorn, Inc.
- Category
- Drug
- Hazard
- Affected units
- 177,439
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot#: a) 3192827
- Exp 10/31/2022
- 3196136
- Exp 12/31/2022
- 3202198
- Exp 07/31/2023
- 3203658
- 3209114
- Exp 11/30/2023
- 3203851
- Exp 02/29/2024
- b) 3191254
- Exp 09/30/2022
- 3192820
- 3192822
- 3192824
- 3192825
- 3196141
- Exp 01/31/2023
- 3196143
Distribution
Part of a larger recall action
This product is one of 2 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · impurity
See all →- ModerateAjanta Pharma Recalls Fluphenazine Hydrochloride Tablets Due to Impurity Failure
FDA (Drugs) · 2026-09-16
- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
Similar recalls
- ModerateAkorn Recalls Rifampin for Injection Due to Impurity Specification Failure
FDA (Drugs) · 2014-10-01
- HighRifampin Capsules Recall: Incomplete Stability Studies Due to Manufacturer Closure
FDA (Drugs) · 2023-06-07
- HighPrescription Rifampin Capsules Recalled for Failed Impurity Specifications
FDA (Drugs) · 2023-01-18
- LowAkorn Recalls RIFAMPIN FOR INJECTION Due to Impurity Specifications
FDA (Drugs) · 2015-11-25
- HighRifampin Capsules recalled due to excessive impurity levels
FDA (Drugs) · 2022-10-26
- HighRifampin Antibiotic Capsules Recalled for Subpotency and Failed Specifications
FDA (Drugs) · 2024-02-07